Q2 EPS Estimates for Editas Medicine Increased by Analyst

Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Research analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for shares of Editas Medicine in a note issued to investors on Monday, June 2nd. Zacks Research analyst A. Chakraborty now forecasts that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.66). The consensus estimate for Editas Medicine's current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine's Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.47) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($1.87) EPS, Q1 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.85) EPS.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.08. The business had revenue of $4.66 million during the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative net margin of 340.96% and a negative return on equity of 80.13%. During the same quarter last year, the company earned ($76.00) earnings per share.

Several other brokerages have also commented on EDIT. HC Wainwright started coverage on Editas Medicine in a research report on Monday, April 28th. They issued a "buy" rating and a $3.00 target price for the company. Wall Street Zen upgraded shares of Editas Medicine from a "sell" rating to a "hold" rating in a research note on Wednesday, May 14th. Robert W. Baird reduced their price target on shares of Editas Medicine from $8.00 to $4.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Finally, Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $5.36.

Editas Medicine Trading Down 1.1%

EDIT stock traded down $0.02 during mid-day trading on Wednesday, hitting $1.80. 3,176,169 shares of the company were exchanged, compared to its average volume of 2,563,543. The firm has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $1.54. Editas Medicine has a twelve month low of $0.91 and a twelve month high of $6.22. The company has a market capitalization of $150.68 million, a PE ratio of -0.70 and a beta of 2.15.

Insider Activity

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total transaction of $26,130.24. Following the completion of the sale, the chief executive officer now directly owns 280,282 shares of the company's stock, valued at approximately $482,085.04. The trade was a 5.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 16,364 shares of company stock valued at $28,146 over the last three months. 2.10% of the stock is owned by insiders.

Institutional Trading of Editas Medicine

Several institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC increased its holdings in Editas Medicine by 288.5% in the first quarter. Acadian Asset Management LLC now owns 752,162 shares of the company's stock valued at $869,000 after purchasing an additional 558,567 shares during the last quarter. SCS Capital Management LLC acquired a new position in Editas Medicine during the first quarter valued at approximately $41,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Editas Medicine by 122.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company's stock valued at $3,016,000 after purchasing an additional 1,430,000 shares in the last quarter. State of Wyoming acquired a new stake in Editas Medicine in the first quarter worth $51,000. Finally, Ieq Capital LLC boosted its position in shares of Editas Medicine by 551.0% during the first quarter. Ieq Capital LLC now owns 160,370 shares of the company's stock worth $186,000 after purchasing an additional 135,736 shares in the last quarter. Institutional investors own 71.90% of the company's stock.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.